Tags : COAST-W trials

Shots: The two P-III trials i.e. COAST-V (N=341) & COAST-W (N=316) involves assessing of Taltz (80/160 mg, q4w/q2w) SC vs adalimumab, or PBO in patients with AS never undergone bDMARD drug and intolerant to TNF inhibitors respectively COAST-V and COAST-W Results: @16 wks.: ASAS40 (48%, 25%; 52% ,31% vs 18%, 13%); ASAS20 (64%, 48%; 69%, […]Read More